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adequacy; second, if a measure of urea removal were to be
used, whether a simple urea reduction ratio is acceptable
or whether a measure that incorporates a normalizing
factor is necessary; and finally – whether the widespread
use of V as this normalizing factor is valid. Jenkins’
criticisms relate to the second point whereas our paper
addressed the third.
Focusing solely on normalized urea clearance presents a
flawed view of dialysis adequacy. There are many other
facets. Middle molecule removal is important. Reanalysis
of data from the HEMO study has demonstrated that
retention of b2 microglobulin was associated with in-
creased mortality.2 In addition to solute clearances, dialysis
prescription encompasses other goals, including sodium
and water, divalent ion and acid-base homeostasis. Dialysis
hypotension is more likely to occur when dialysis session
time is shortened, because of increased ultrafiltration rates,
and failure to achieve adequate sodium removal with
increased interdialytic weight gains.
Although we have criticized the appropriateness of the
use of Kt/V in prescribing hemodialysis, we do believe that
an assessment of the amount of dialysis delivered is vital,
unless very long and/or very frequent dialysis sessions
are employed. Normalized urea clearance, although not
perfect, is a useful marker of adequacy, though we believe
it could be used more astutely. Our paper proposes that the
normalizing factor should reflect metabolic activity, as use
of V may risk under-dialysis in women and small men. We
suggest that this should be borne in mind while we
continue to use Kt/V, and that the adequacy targets should
be adjusted in these two groups.
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To the Editor: We have read with interest the article by
Hai-Lu Zhao et al.1 on fat redistribution and adipocyte
transformation in uninephrectomized rats. Among numerous
interesting findings, the authors demonstrate increased
ectopic fat deposits in remnant kidneys and other solid
organs of chronic kidney disease animals. The authors
speculate on the possible mechanisms, taking into account
increased lipid production. This hypothesis is strengthened
by demonstrating that expression of HMG-CoA reductase,
the rate-limiting enzyme in cholesterologenesis pathway, is
increased in remnant kidneys.
We would like to confirm these results and highlight the
potential role of sterol regulatory element-binding proteins
(SREBPs) in the above-mentioned disturbances. SREBPs are
nuclear transcription factors that are currently regarded as
the major regulators of both cholesterologenesis and
lipogenesis.
We have shown that both gene expression and protein
abundance of SREBPs are increased in white adipose tissue2
and livers3 of chronic kidney disease rats. Moreover, increase
in SREBP expression has been demonstrated in kidneys of
diabetic mice4 and in experimental age-related nephropathy,5
where it has been clearly linked to lipid deposition in
glomeruli, and consequently to mesangial expansion, glo-
merulosclerosis, and proteinuria.
These results complement the findings demonstrated by
Zhao et al. as they bring us closer to elucidating the issue of
altered lipid metabolism in the course of chronic kidney
disease.3
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